A new trading day began on Tuesday, with EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock price up 4.85% from the previous day of trading, before settling in for the closing price of $9.49. EYPT’s price has ranged from $3.91 to $13.98 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 15.65% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -31.19%. With a float of $59.81 million, this company’s outstanding shares have now reached $68.81 million.
In an organization with 165 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 93.29%, operating margin of -287.94%, and the pretax margin is -261.75%.
EyePoint Pharmaceuticals Inc (EYPT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of EyePoint Pharmaceuticals Inc is 13.08%, while institutional ownership is 96.93%. The most recent insider transaction that took place on May 19 ’25, was worth 29,950. In this transaction Director of this company bought 5,000 shares at a rate of $5.99, taking the stock ownership to the 36,500 shares. Before that another transaction happened on May 16 ’25, when Company’s Director bought 5,000 for $5.81, making the entire transaction worth $29,050. This insider now owns 31,500 shares in total.
EyePoint Pharmaceuticals Inc (EYPT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.73% during the next five years compared to 15.65% growth over the previous five years of trading.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
Here are EyePoint Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.93 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.75 million. That was inferior than the volume of 0.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.47%.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 88.05%, which indicates a significant increase from 71.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.76 in the past 14 days, which was higher than the 0.56 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.70, while its 200-day Moving Average is $7.84. However, in the short run, EyePoint Pharmaceuticals Inc’s stock first resistance to watch stands at $10.14. Second resistance stands at $10.33. The third major resistance level sits at $10.60. If the price goes on to break the first support level at $9.68, it is likely to go to the next support level at $9.41. Assuming the price breaks the second support level, the third support level stands at $9.22.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
With a market capitalization of 684.68 million, the company has a total of 68,811K Shares Outstanding. Currently, annual sales are 43,270 K while annual income is -130,870 K. The company’s previous quarter sales were 24,450 K while its latest quarter income was -45,200 K.
